Simvastatin Plus Rifaximin in Decompensated Cirrhosis
Status:
Completed
Trial end date:
2018-03-12
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to investigate whether the combination of two different
drugs, simvastatin and rifaximin, is safe in the treatment of patients with decompensated
cirrhosis.
The secondary purpose is to see if this combination results in an improvement in inflammation
markers in patients with cirrhosis and in an improvement in analytic parameters of
progression of liver disease.